Literature DB >> 25856668

PMS2 monoallelic mutation carriers: the known unknown.

McKinsey L Goodenberger1, Brittany C Thomas1, Douglas Riegert-Johnson2, C Richard Boland3, Sharon E Plon4, Mark Clendenning5, Aung Ko Win6, Leigha Senter7, Steven M Lipkin8, Zsofia K Stadler9, Finlay A Macrae10, Henry T Lynch11, Jeffrey N Weitzel12, Albert de la Chapelle7, Sapna Syngal13, Patrick Lynch14, Susan Parry15, Mark A Jenkins6, Steven Gallinger16, Spring Holter16, Melyssa Aronson16, Polly A Newcomb17, Terrilea Burnett18, Loïc Le Marchand18, Pavel Pichurin19, Heather Hampel7, Jonathan P Terdiman20, Karen H Lu21, Stephen Thibodeau1, Noralane M Lindor22.   

Abstract

Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.Genet Med 18 1, 13-19.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25856668      PMCID: PMC4834863          DOI: 10.1038/gim.2015.27

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  48 in total

1.  Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer.

Authors:  Olivia Will; Luis G Carvajal-Carmona; Patricia Gorman; Kimberley M Howarth; Angela M Jones; Guadalupe M Polanco-Echeverry; Jo-Anne Chinaleong; Thomas Günther; Andrew Silver; Susan K Clark; Ian Tomlinson
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

2.  The frequency of previously undetectable deletions involving 3' Exons of the PMS2 gene.

Authors:  Cecily P Vaughn; Christine L Baker; Wade S Samowitz; Jeffrey J Swensen
Journal:  Genes Chromosomes Cancer       Date:  2012-09-25       Impact factor: 5.006

3.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

Review 4.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer.

Authors:  Francis M Giardiello; John I Allen; Jennifer E Axilbund; C Richard Boland; Carol A Burke; Randall W Burt; James M Church; Jason A Dominitz; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David A Lieberman; Douglas J Robertson; Sapna Syngal; Douglas K Rex
Journal:  Gastrointest Endosc       Date:  2014-08       Impact factor: 9.427

5.  Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene.

Authors:  M De Rosa; C Fasano; L Panariello; M I Scarano; G Belli; A Iannelli; F Ciciliano; P Izzo
Journal:  Oncogene       Date:  2000-03-23       Impact factor: 9.867

6.  Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.

Authors:  Sridharan Gururangan; Wendy Frankel; Russell Broaddus; Mark Clendenning; Leigha Senter; Marie McDonald; James Eastwood; David Reardon; James Vredenburgh; Jennifer Quinn; Henry S Friedman
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

7.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

Review 8.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

9.  Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC?

Authors:  J D Trimbath; G M Petersen; S H Erdman; M Ferre; M C Luce; F M Giardiello
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

10.  PMS2 involvement in patients suspected of Lynch syndrome.

Authors:  Renée C Niessen; Jan H Kleibeuker; Helga Westers; Paul O J Jager; Dennie Rozeveld; Krista K Bos; Wytske Boersma-van Ek; Harry Hollema; Rolf H Sijmons; Robert M W Hofstra
Journal:  Genes Chromosomes Cancer       Date:  2009-04       Impact factor: 5.006

View more
  23 in total

1.  Exploring the effect of ascertainment bias on genetic studies that use clinical pedigrees.

Authors:  John Michael O Ranola; Ginger J Tsai; Brian H Shirts
Journal:  Eur J Hum Genet       Date:  2019-07-11       Impact factor: 4.246

2.  Germline Genetic Features of Young Individuals With Colorectal Cancer.

Authors:  Elena M Stoffel; Erika Koeppe; Jessica Everett; Peter Ulintz; Mark Kiel; Jenae Osborne; Linford Williams; Kristen Hanson; Stephen B Gruber; Laura S Rozek
Journal:  Gastroenterology       Date:  2017-11-14       Impact factor: 22.682

Review 3.  Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.

Authors:  Laura Valle; Eduardo Vilar; Sean V Tavtigian; Elena M Stoffel
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

4.  Resolving misalignment interference for NGS-based clinical diagnostics.

Authors:  Che-Yu Lee; Hai-Yun Yen; Alan W Zhong; Hanlin Gao
Journal:  Hum Genet       Date:  2020-09-11       Impact factor: 4.132

5.  Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria.

Authors:  Maribel González-Acosta; Jesús Del Valle; Matilde Navarro; Bryony A Thompson; Sílvia Iglesias; Xavier Sanjuan; María José Paúles; Natàlia Padilla; Anna Fernández; Raquel Cuesta; Àlex Teulé; Guido Plotz; Juan Cadiñanos; Xavier de la Cruz; Francesc Balaguer; Conxi Lázaro; Marta Pineda; Gabriel Capellá
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

Review 6.  The changing landscape of Lynch syndrome due to PMS2 mutations.

Authors:  J Blount; A Prakash
Journal:  Clin Genet       Date:  2018-03-15       Impact factor: 4.438

7.  Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome.

Authors:  Shahid Mahmood Baig; Ambrin Fatima; Muhammad Tariq; Tahir Naeem Khan; Zafar Ali; Mohammad Faheem; Humera Mahmood; Patrick Killela; Matthew Waitkus; Yiping He; Fangping Zhao; Sizhen Wang; Yuchen Jiao; Hai Yan
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

Review 8.  Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.

Authors:  Patrick M Boland; Matthew B Yurgelun; C Richard Boland
Journal:  CA Cancer J Clin       Date:  2018-02-27       Impact factor: 508.702

Review 9.  Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.

Authors:  M J Hall; E I Obeid; S C Schwartz; G Mantia-Smaldone; A D Forman; M B Daly
Journal:  Gynecol Oncol       Date:  2016-01-23       Impact factor: 5.482

10.  Response to ten Broeke and Nielsen.

Authors:  Noralane M Lindor; McKinsey L Goodenberger
Journal:  Genet Med       Date:  2015-08       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.